Literature DB >> 10826588

Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn.

S Jaegtvik1, A Husebekk, B Aune, P Oian, L B Dahl, B Skogen.   

Abstract

Eleven thousand one hundred pregnant women were genotyped for human platelet antigen HPA 1, and 198 HPA 1bb women were followed in the pregnancy with quantitative assay for anti-HPA la antibodies. Antibodies were detected in 24 women, and nine children were born with severe thrombocytopenia (< 50x10(9)/L). All mothers with high levels of antibodies were delivered of children with severe thrombocytopenia. None of the newborn infants had clinical signs of intra-cranial haemorrhage. The level of maternal anti-HPA 1a antibodies is predictive for fetal thrombocytopenia and may be used in decisions related to time and mode of delivery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10826588     DOI: 10.1111/j.1471-0528.2000.tb13315.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  8 in total

1.  Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.

Authors:  Jens Kjeldsen-Kragh; Dean A Fergusson; Mette Kjaer; Lani Lieberman; Andreas Greinacher; Michael F Murphy; James Bussel; Tamam Bakchoul; Stacy Corke; Gérald Bertrand; Dick Oepkes; Jillian M Baker; Heather Hume; Edwin Massey; Cecile Kaplan; Donald M Arnold; Shoma Baidya; Greg Ryan; Helen F Savoia; Denise Landry; Nadine Shehata
Journal:  Blood Adv       Date:  2020-07-28

2.  A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter.

Authors:  Ulrich J H Sachs; Ines Socher; Christian G Braeunlich; Hartmut Kroll; Gregor Bein; Sentot Santoso
Journal:  Immunology       Date:  2006-06-23       Impact factor: 7.397

3.  Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism.

Authors:  D J Jackson; M F Murphy; P W Soothill; G F Lucas; C J Elson; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 4.  Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management.

Authors:  Julie A Peterson; Janice G McFarland; Brian R Curtis; Richard H Aster
Journal:  Br J Haematol       Date:  2013-02-06       Impact factor: 6.998

Review 5.  Neonatal thrombocytopenia: causes and management.

Authors:  I Roberts; N A Murray
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-09       Impact factor: 5.747

6.  Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.

Authors:  Cedric Ghevaert; David A Wilcox; Juan Fang; Kathryn L Armour; Mike R Clark; Willem H Ouwehand; Lorna M Williamson
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

7.  The development of severe neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies is correlated to maternal ABO genotypes.

Authors:  Maria Therese Ahlen; Anne Husebekk; Mette Kjær Killie; Jens Kjeldsen-Kragh; Martin L Olsson; Bjørn Skogen
Journal:  Clin Dev Immunol       Date:  2011-11-02

Review 8.  Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.

Authors:  Heidi Tiller; Anne Husebekk; Maria Therese Ahlen; Tor B Stuge; Bjørn Skogen
Journal:  Int J Womens Health       Date:  2017-04-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.